CERo Therapeutics Holdings, Inc. Common Stock Cash Flow Conversion Efficiency
CERo Therapeutics Holdings, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a cash flow conversion efficiency ratio of 0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Million) by net assets ($-30.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. This chart illustrates how CERo Therapeutics Holdings, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CERO share price today for real-time trading data and today's change.
CERo Therapeutics Holdings, Inc. Common Stock Cash Flow Conversion Ratio Explained
CERo Therapeutics Holdings, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CERo Therapeutics Holdings, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CERo Therapeutics Holdings, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see CERo Therapeutics Holdings, Inc. Common market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ProstaLund AB
ST:PLUN
|
-0.052x |
|
Strikewell Energy Corp
V:SKK
|
0.000x |
|
Kollect on Demand Holding Ab
ST:KOLL
|
-0.012x |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
0.143x |
|
Zephyr Energy PLC
LSE:ZPHR
|
0.043x |
|
Glen Eagle Resources Inc
V:GER
|
0.307x |
|
EUROPA MET. LTD POST CONS
F:WRE1
|
N/A |
|
Onward Opportunities Ltd
LSE:ONWD
|
-0.036x |
Annual Cash Flow Conversion Efficiency for CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. Review CERO financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.45 Million | $-16.08 Million | 2.952x | -3.39% |
| 2024-12-31 | $-1.89 Million | $-5.79 Million | 3.056x | +2119.92% |
| 2023-12-31 | $-42.06 Million | $-5.79 Million | 0.138x | +131.12% |
| 2022-12-31 | $2.47 Million | $-1.09 Million | -0.442x | -10742.21% |
| 2021-12-31 | $170.83 Million | $-697.11K | -0.004x | -- |
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.